HUP0303315A2 - Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények - Google Patents
Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0303315A2 HUP0303315A2 HU0303315A HUP0303315A HUP0303315A2 HU P0303315 A2 HUP0303315 A2 HU P0303315A2 HU 0303315 A HU0303315 A HU 0303315A HU P0303315 A HUP0303315 A HU P0303315A HU P0303315 A2 HUP0303315 A2 HU P0303315A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- prostaglandin
- atom
- carbon atoms
- antithrombotic agent
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title abstract 5
- 229960004676 antithrombotic agent Drugs 0.000 title abstract 4
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 3
- 230000002785 anti-thrombosis Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 2
- -1 COOA Chemical group 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 208000023819 chronic asthma Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát gyógyszerkészítmény képezi, ami legalább egyfoszfodiészteráz V inhibitort és/vagy ennek gyógyászatilag elfogadhatósóit és/vagy szolvátjait, valamint legalább egy trombózisellenes szerttartalmaz. A találmány további tárgyai azok a gyógyszerkészítmények,amelyek tartalmaznak legalább egy (I) általános képletű vegyületet,ahol a képletben R1 és R2 jelentése egymástól függetlenülhidrogénatom, A, OH, OA vagy Hal, vagy R1 és R2 jelentése együtt 3-5szénatomos alkiléncsoport, -O-CH2-CH2-, -CH2-O-CH2-, -O-CH2-O- vagy -O-CH2-CH2-O- csoport, R3 és R4 jelentése egymástól függetlenülhidrogénatom vagy A csoport, X jelentése R5, R6 vagy R7, amelyekmindegyike R8 csoporttal monoszubsztituált, R5 jelentése lineáris vagyelágazó láncú 1-10 szénatomos alkiléncsoport, amelyben egy vagy kétCH2-csoportot -CH=CH-csoport helyettesíthet, O, S vagy SO, R6jelentése 5-12 szénatomos cikloalkil- vagy cikloalkilalkiléncsoport;R7 jelentése fenil- vagy fenilmetilcsoport, R8 jelentése COOH, COOA,CONH2, CONHA, CON(A)2 vagy CN csoport; A jelentése 1-6 szénatomosalkilcsoport; Hal jelentése fluoratom, klóratom, brómatom vagyjódatom; és/vagy ennek fiziológiailag elfogadható sóit és/vagyszolvátjait és a) legalább egy trombózisellenes szert, vagy b)legalább egy kalcium antagonistát vagy c) legalább egy prosztaglandintvagy prosztaglandinszármazékot. A találmány további tárgya a fentigyógyszerkészítmény alkalmazása angina, magas vérnyomás, fokozottkisvérköri nyomás, vértolulásos szívelégtelenség (CHF), krónikuselzáródásos tüdőbetegség (COPD), cor pulmonale, dextrokardiáliselégtelenség, ateroszklerózis, szív-véredények lecsökkentnyitottságával együtt járó állapotok, periferális érbetegségek,stroke, bronchitis, allergiás asztma, krónikus asztma, allergiásnátha, zöldhályog, irritábilis bél szindróma, tumor, veseelégtelenség,máj cirrhosis és női szexuális diszfunkció kezelésére alkalmasgyógyszer előállítására, valamint (a) hatásos mennyiségű[7-(3-klór-4-metoxibenzilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]pirimidin-5-il-metoxi] ecetsav etanolaminsót és (b) hatásos mennyiségűtrombózisellenes szer vagy legalább egy kalcium antagonista vagylegalább egy prosztaglandin vagy prosztaglandinszármazék egymástólelkülönített egységeit tartalmazó kit. Ó
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10063224A DE10063224A1 (de) | 2000-12-19 | 2000-12-19 | Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica |
| DE2000163882 DE10063882A1 (de) | 2000-12-21 | 2000-12-21 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten |
| DE2000164993 DE10064993A1 (de) | 2000-12-23 | 2000-12-23 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate |
| PCT/EP2001/013916 WO2002049651A1 (de) | 2000-12-19 | 2001-11-28 | Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0303315A2 true HUP0303315A2 (hu) | 2004-01-28 |
Family
ID=27214208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303315A HUP0303315A2 (hu) | 2000-12-19 | 2001-11-28 | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040063730A1 (hu) |
| EP (1) | EP1343506A1 (hu) |
| JP (1) | JP2004516270A (hu) |
| KR (1) | KR20030059349A (hu) |
| CN (1) | CN1481244A (hu) |
| AR (1) | AR035676A1 (hu) |
| AU (1) | AU2002229573A1 (hu) |
| BR (1) | BR0115995A (hu) |
| CA (1) | CA2431077A1 (hu) |
| CZ (1) | CZ20031776A3 (hu) |
| HU (1) | HUP0303315A2 (hu) |
| MX (1) | MXPA03005393A (hu) |
| NO (1) | NO20032773L (hu) |
| PL (1) | PL362513A1 (hu) |
| SK (1) | SK8192003A3 (hu) |
| WO (1) | WO2002049651A1 (hu) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035531A1 (es) * | 2001-01-22 | 2004-06-02 | Novartis Ag | Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos |
| DE60237425D1 (de) * | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| KR100468352B1 (ko) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
| AU2004234158B2 (en) | 2003-04-29 | 2010-01-28 | Pfizer Inc. | 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension |
| CA2525970C (en) * | 2003-05-15 | 2011-03-22 | Roskamp Research, Llc | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| JP2007532526A (ja) * | 2004-04-07 | 2007-11-15 | ファイザー・インク | ピラゾロ［４，３−ｄ］ピリミジン類 |
| ES2449340T3 (es) | 2007-03-30 | 2014-03-19 | Amgen Inc. | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales |
| JP5411145B2 (ja) * | 2007-10-05 | 2014-02-12 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法 |
| US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
| NO2315587T3 (hu) * | 2008-08-13 | 2018-03-24 | ||
| JP6925272B2 (ja) * | 2015-01-28 | 2021-08-25 | リアルイン ライフ サイエンス リミテッド | ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| JP7076432B2 (ja) | 2016-09-09 | 2022-05-27 | インサイト・コーポレイション | Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法 |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TWI778050B (zh) | 2017-04-21 | 2022-09-21 | 美商醫肯納腫瘤學公司 | 吲哚ahr抑制劑及其用途 |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| PE20210397A1 (es) | 2018-02-20 | 2021-03-02 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| EP4010338A1 (en) | 2019-08-06 | 2022-06-15 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
| MX2022006308A (es) | 2019-11-26 | 2022-06-22 | Ikena Oncology Inc | Derivados de carbazol polimorfos y usos de los mismos. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
| JPS5459266A (en) * | 1977-10-14 | 1979-05-12 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analogs and their preparation |
| FR2568774B2 (fr) * | 1984-05-30 | 1989-05-19 | Choay Sa | Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique |
| FR2672601B1 (fr) * | 1991-02-08 | 1994-10-14 | Synthelabo | Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique. |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| DE19709877A1 (de) * | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| EP1027054A4 (en) * | 1997-10-28 | 2002-11-04 | Vivus Inc | LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION |
| DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| DE10058662A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
| DE10103647A1 (de) * | 2001-01-27 | 2002-08-01 | Merck Patent Gmbh | Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates |
-
2001
- 2001-11-28 CN CNA018209165A patent/CN1481244A/zh active Pending
- 2001-11-28 MX MXPA03005393A patent/MXPA03005393A/es not_active Application Discontinuation
- 2001-11-28 BR BR0115995-0A patent/BR0115995A/pt not_active Application Discontinuation
- 2001-11-28 JP JP2002550991A patent/JP2004516270A/ja active Pending
- 2001-11-28 AU AU2002229573A patent/AU2002229573A1/en not_active Abandoned
- 2001-11-28 CA CA002431077A patent/CA2431077A1/en not_active Abandoned
- 2001-11-28 CZ CZ20031776A patent/CZ20031776A3/cs unknown
- 2001-11-28 EP EP01990452A patent/EP1343506A1/de not_active Withdrawn
- 2001-11-28 KR KR10-2003-7008078A patent/KR20030059349A/ko not_active Application Discontinuation
- 2001-11-28 HU HU0303315A patent/HUP0303315A2/hu unknown
- 2001-11-28 SK SK819-2003A patent/SK8192003A3/sk unknown
- 2001-11-28 PL PL01362513A patent/PL362513A1/xx unknown
- 2001-11-28 WO PCT/EP2001/013916 patent/WO2002049651A1/de not_active Application Discontinuation
- 2001-11-28 US US10/451,105 patent/US20040063730A1/en not_active Abandoned
- 2001-12-19 AR ARP010105888A patent/AR035676A1/es unknown
-
2003
- 2003-06-18 NO NO20032773A patent/NO20032773L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0115995A (pt) | 2004-01-13 |
| KR20030059349A (ko) | 2003-07-07 |
| CN1481244A (zh) | 2004-03-10 |
| SK8192003A3 (en) | 2003-10-07 |
| CZ20031776A3 (cs) | 2003-09-17 |
| EP1343506A1 (de) | 2003-09-17 |
| AR035676A1 (es) | 2004-06-23 |
| WO2002049651A1 (de) | 2002-06-27 |
| JP2004516270A (ja) | 2004-06-03 |
| CA2431077A1 (en) | 2002-06-27 |
| MXPA03005393A (es) | 2003-09-25 |
| NO20032773D0 (no) | 2003-06-18 |
| US20040063730A1 (en) | 2004-04-01 |
| AU2002229573A1 (en) | 2002-07-01 |
| NO20032773L (no) | 2003-06-18 |
| PL362513A1 (en) | 2004-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303315A2 (hu) | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények | |
| HUP0400818A2 (hu) | Tieno[2,3-d]pirimidinek alkalmazása és az ezeket tartalmazó gyógyszerkészítmények | |
| KR20080076961A (ko) | Ｐｄｅ５ 억제제 및 무스카린성 길항제를 포함하는ｌｕｔｓ의 치료를 위한 약제학적 조합물 | |
| TW200602035A (en) | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| JP2009504746A5 (hu) | ||
| JP2017523219A5 (hu) | ||
| HUP0303289A2 (hu) | Tienopirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények | |
| JP2007525533A5 (hu) | ||
| RU2004114239A (ru) | Производные пиримидина | |
| HUP0303005A2 (hu) | Pirazolo[4,3-d]pirimidineket vagy tienopirimidineket és endotelin receptor antagonistákat tartalmazó gyógyszerkészítmények | |
| KR20090112673A (ko) | 고안압증 치료용 이소소르비드 모노니트레이트 유도체 | |
| EP2752190B1 (en) | Method for improving therapy for autoimmune diseases such as rheumatoid arthritis | |
| HUP0302720A2 (hu) | Pirazolo[4,3d]pirimidin-származékok alkalmazása gyógyszerkészítmények előállítására | |
| DK1458381T3 (da) | Triazoler som oxytocinantagonister | |
| IL160082A0 (en) | Quinoline derivatives and use thereof as antitumor agents | |
| HUP0401368A2 (hu) | Tienopirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandin származékokat tartalmazó gyógyszerkészítmények | |
| WO2009007895A4 (en) | A compound showing anti-inflammatory activity and antiviral activity, pharmaceutical compositions comprising the same, a process for obtaining the same and use of the same in the treatment of epidemic keratoconjunctivites and herpetic stromal keratis | |
| HUP0202614A2 (hu) | Tienopirimidin-vegyületek alkalmazása | |
| RU2021119947A (ru) | Лечебное применение пирролопиримидинового соединения и твердая фармацевтическая композиция пирролопиримидинового соединения | |
| RU2003108860A (ru) | Тиенопиримидины | |
| HUP0303075A2 (hu) | Az 5HT4 receptor antagonisták használata bizonyos kardiovaszkuláris állapotok megelőzésében vagy kezelésében és az erre alkalmas gyógyszerkészítmények előállítására | |
| JP2004123558A (ja) | 片頭痛の予防、治療剤 | |
| MX2022016497A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica. | |
| JPWO2020135401A5 (hu) |